Academic:
Licensed from Medical School, University of Valencia. General Physician, Hospital Clínico Universitario of Valencia. Residency on Obstetrics & Gynaecology, Hospital Universitario La Fe of Valencia. Doctoral Courses, University of Valencia. Clinical Fellowship of Human Reproduction at The Hospital of the University of Pennsylvania, Philadelphia, USA. Staff at the Human Reproduction unit, Hospital Universitario La Fe of Valencia. Postdoctoral Research Project: «Influence of intrafollicular LH on oocyte quality in In Vitro Fertilization» qualified with Excellent «cum laude» at the University of Valencia, under the direction of Prof. Alberto Romeu from Hospital Universitario La Fe of Valencia, and Prof. Luis Blasco from The Hospital of The University of Pennsylvania, Philadelphia, USA. Gynaecologist of The Human Reproduction Unit at The Instituto Valenciano de Infertilidad, Valencia, Spain. Medical Director of the Human Reproduction Unit at The Instituto Valenciano de Infertilidad, Valencia, Spain. Director of The Instituto Valenciano de Infertilidad in Valencia, Spain.
Other courses-prices:
Statistical Methods in Health Sciences, (300 hours), Universidad Autónoma de Barcelona. Multivariate Analysis (240 hours), Universidad Autónoma de Barcelona. European Diplomat in Gynaecological Endoscopy, Universidad de Alcalá de Henares and University of Clermont-Ferrand. Master on Design of Research projects, Universidad Autónoma de Barcelona. ASRM General Program Paper Prize. MBA on Healthcare management, IMF Business School, Madrid, Spain. Management Essentials (45 hours), Harvard Business School. GCP E6 (R2) for The Global Health Network.
Clinical Studies in Relevant Area (including responsibilities):
Endometrial development in oocyte donors treated with either high- or standard- dose GnRH antagonist compared to tratment with a GnRH agonist or in natural cycles, Sub-investigator.
Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone and its relationship with cycle outcome, Principal Investigator.
Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonist, Principal Investigator.
GnRH agonist administration at the time of implantation in intrauterine insemination cycles, Sub-investigator.
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles, Principal Investigator.
Embryoaneuploidy in natural ve stimulated cycles, Sub-investigator.
Endometrial receptivity in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis, Sub-investigator.
Human derived recombinant FSH, Phase II, Principal Investigator.
Barusiban to prevent uterine contractions in IVF patients, Principal Investigator and signing investigator.
Serum AMH and correlation with antral follicle count, Principal Investigator.
Recombinant LH in low responders, Principal Investigators.
Human derived recombinant FSH, phase III, Principal Investigator.
Luteal phase support with duphaston, Principal Investigator.
Placebo controlled study of nolasiban to improve pregnacy rates in women undergoing IVF/ICSI.
Ongoing pregnancy rates in oocyte donation according to serum P levels de day of embryo transfer, Sub-investigator.
Follicular steroidgenesis in controlled ovarian stimulation, Principal Investigator.
Comparison of hhCG with hCG+β in the early prediction of ongoing pregnacy after in-vitro fertilization and embryo transfer, Principal Investigator.
A randomised, double-blind, placebo-controlled, parallel-group, dose-range trial to investigate the efficacy and safety of FE 999302 as add-on tratment to follitropin delta (REKOVELLE) in women undergoing controlled ovarian stimulation in a long GnRH agonist protocol, Principal Investigator.
